ClinicalTrials.gg
CompletedNCT00127933Updated Aug 10, 2011Results posted

XeNA Study - A Study of Xeloda (Capecitabine) in Patients With Invasive Breast Cancer

A Phase 4 interventional study of capecitabine [Xeloda] and Taxotere in Breast Cancer, sponsored by Hoffmann-La Roche. Completed at 38 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-08-10.

Sponsored by Hoffmann-La Roche · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
157
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 264 studies testing docetaxel in Breast Neoplasms — 19 open to participants now, 26 under way, 8 of them phase 3. Docetaxel · Breast Neoplasms.

Enrollment
70th of 248
157 · median 68
Started
2005
with 18 others
Phase 4
5 of 264
none open now
Registered
61st of 264
by date
Lead sponsor
16 of 264
Hoffmann-La Roche

Among the 264 studies testing docetaxel in Breast Neoplasms, this one is the 70th largest by enrollment of the 248 interventional ones that give a count, is one of 19 that started in 2005, is one of 5 in phase 4, and was the 61st registered.

Breast Neoplasms

14,843 studies on the registry are indexed under Breast Neoplasms; 3,319 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

19 of the 264 studies testing docetaxel in Breast Neoplasms are open now, in 9 countries. Recruiting first, the newest first:

14 more — sign in →

By country, each count listing its studies:

All 19 open studies →

About docetaxel

Docetaxel: first FDA approval 1996 (TAXOTERE), first EMA approval 1995. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,573 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 264 studies testing docetaxel in Breast Neoplasms, or all of them as a file.
02

Study summary

This single arm study stratified patients into two treatment cohorts based on HER2-neu overexpression/amplification. Each cohort will be independently powered for the primary endpoint. The study will evaluate the efficacy, safety and impact on quality of life of treatment with oral Xeloda plus intravenous (iv) Taxotere (docetaxel). Patients with HER2-neu negative breast cancer will receive chemotherapy alone with oral Xeloda plus intravenous (iv) Taxotere (docetaxel). Patients with HER2-neu positive breast cancer, will receive the same chemotherapy in combination with intravenous (iv) Herceptin (trastuzumab). Patients will receive 3-weekly cycles of treatment with Xeloda (825mg/m2 oral administration [po] twice daily (bid) on days 1-14) + Taxotere (75mg/m2 iv on day 1). HER2-neu positive patients will also receive Herceptin (loading dose of 4mg/kg iv followed by 2mg/kg iv weekly). The anticipated time on study treatment is 3-12 months, and the target sample size is 100-500 individuals.

03

Conditions studied

  • Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • women >=18 years of age;
  • newly diagnosed;
  • infiltrating (invasive) -neu-negative or HER2-neu-positive breast cancer.

Exclusion criteria

Exclusion Criteria:

  • evidence of disease, except ipsilateral (same side) axillary lymph nodes;
  • previous systemic or local primary treatment.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
157 participants (actual)

Study arms

  • Experimental
    HER2-NEU Positive

    Drug: capecitabine [Xeloda] · Drug: Taxotere · Drug: Herceptin (HER2-neu positive patients only)

  • Experimental
    HER2-NEU Negative

    Drug: capecitabine [Xeloda] · Drug: Taxotere

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Assessed for Pathological Complete Response (pCR) Plus Near Complete (npCR) in Primary Breast Tumor at Time of Definitive Surgery

    Pathological complete response was defined as the absence of histological evidence of invasive breast cancer cells in the tissue specimen removed from the breast after 4 cycles of preoperative treatment. Near pCR (npCR) was defined as the presence of invasive tumor cells with a size of 5 mm or less in aggregate in the tissue specimen removed from the breast after 4 cycles of preoperative treatment. Only pathological assessments occurring prior to the first date of adjuvant treatment were included in the analysis of pCR rate.

    Time frame: at the time of definitive surgery; after four 3-week cycles (3-4 months)

Secondary outcomes

  1. Percentage of Participants With Complete Pathological Response in the Primary Breast Tumor at the Time of Definitive Surgery

    Pathological complete response was defined as the absence of histological evidence of invasive breast cancer cells in the tissue specimen removed from the breast after 4 cycles of preoperative treatment.

    Time frame: at the time of definitive surgery; after four 3-week cycles (3-4 months)

  2. Percentage of Participants With Overall Clinical Response (Complete Response (CR) Plus Partial Response (PR))

    The best overall response in an individual patient, according to RECIST, during preoperative treatment was the best response recorded from the start of study treatment until disease progression/recurrence (taking as reference for PD the smallest measurements recorded since the baseline assessment) or completion of preoperative treatment. Patients with CR or PR were considered responders. Patients with no tumor assessment after the start of study treatment were considered nonresponders.

    Time frame: post 2 and 4, 3-week cycles of treatment

  3. Percentage of Participants With Local Recurrence

    Local recurrence was defined as evidence of recurrent carcinoma in the same breast where it was diagnosed initially before preoperative treatment.

    Time frame: 30 - 1102 days

  4. Participants With Disease-Free Survival

    Disease-free survival was defined as the time from date of surgery to date of first evidence of cancer recurrence in the breast (ie, local or distant recurrence or contra lateral disease) or death from any cause, whichever came first. Patients who were alive or withdrawn from the study and had no evidence of disease recurrence and for whom there was CRF evidence that evaluations had been made were censored at the date of the last clinical follow-up assessment when the patient was known to be disease free.

    Time frame: 30 - 1102 days

  5. Participants With Overall Survival

    Overall survival was defined as the time from date of start of study treatment to the date of death, regardless of the cause of death. Patients who were alive at the time of the analysis were censored at the date of the last follow-up assessment. Patients without follow-up assessment were censored at the day of the last dose. Patients with no post-baseline information were censored at the start of study treatment.

    Time frame: 22 - 1191 days

07

Results

Posted Aug 10, 2011

Participant flow

Participant flow — Overall Study
MilestoneHER2-Neu NegativeHER2-Neu Positive
Started12334
Pathological response10128
Clinical response12234
Safety population12234
Quality of life population11833
Postoperative9827
Completed12234
Not completed10
Withdrew: Randomized but not dosed10

Outcome measures

PrimaryPercentage of Participants Assessed for Pathological Complete Response (pCR) Plus Near Complete (npCR) in Primary Breast Tumor at Time of Definitive Surgery

Pathological complete response was defined as the absence of histological evidence of invasive breast cancer cells in the tissue specimen removed from the breast after 4 cycles of preoperative treatment. Near pCR (npCR) was defined as the presence of invasive tumor cells with a size of 5 mm or less in aggregate in the tissue specimen removed from the breast after 4 cycles of preoperative treatment. Only pathological assessments occurring prior to the first date of adjuvant treatment were included in the analysis of pCR rate.

Time frame:
at the time of definitive surgery; after four 3-week cycles (3-4 months)
Reported as:
Number · percentage of participants
Percentage of Participants Assessed for Pathological Complete Response (pCR) Plus Near Complete (npCR) in Primary Breast Tumor at Time of Definitive Surgery
percentage of participantsHER2-Neu NegativeHER2-Neu Positive
Percentage of Participants Assessed for Pathological Complete Response (pCR) Plus Near Complete (npCR) in Primary Breast Tumor at Time of Definitive Surgery15.8 (9.7 to 25.4)50.0 (31.9 to 71.3)
SecondaryPercentage of Participants With Complete Pathological Response in the Primary Breast Tumor at the Time of Definitive Surgery

Pathological complete response was defined as the absence of histological evidence of invasive breast cancer cells in the tissue specimen removed from the breast after 4 cycles of preoperative treatment.

Time frame:
at the time of definitive surgery; after four 3-week cycles (3-4 months)
Reported as:
Number · percentage of participants
Percentage of Participants With Complete Pathological Response in the Primary Breast Tumor at the Time of Definitive Surgery
percentage of participantsHER2-Neu NegativeHER2-Neu Positive
Percentage of Participants With Complete Pathological Response in the Primary Breast Tumor at the Time of Definitive Surgery9.9 (5.1 to 18.1)35.7 (19.4 to 57.6)
SecondaryPercentage of Participants With Overall Clinical Response (Complete Response (CR) Plus Partial Response (PR))

The best overall response in an individual patient, according to RECIST, during preoperative treatment was the best response recorded from the start of study treatment until disease progression/recurrence (taking as reference for PD the smallest measurements recorded since the baseline assessment) or completion of preoperative treatment. Patients with CR or PR were considered responders. Patients with no tumor assessment after the start of study treatment were considered nonresponders.

Time frame:
post 2 and 4, 3-week cycles of treatment
Reported as:
Number · percentage of participants
Percentage of Participants With Overall Clinical Response (Complete Response (CR) Plus Partial Response (PR))
percentage of participantsHER2-Neu NegativeHER2-Neu Positive
Percentage of Participants With Overall Clinical Response (Complete Response (CR) Plus Partial Response (PR))23.8 (18.6 to 35.9)23.5 (12.3 to 45.9)
SecondaryPercentage of Participants With Local Recurrence

Local recurrence was defined as evidence of recurrent carcinoma in the same breast where it was diagnosed initially before preoperative treatment.

Time frame:
30 - 1102 days
Reported as:
Number · percentage of participants
Percentage of Participants With Local Recurrence
percentage of participantsHER2-Neu NegativeHER2-Neu Positive
Percentage of Participants With Local Recurrence3.1 (0.6 to 8.7)3.7 (0.1 to 19.0)
SecondaryParticipants With Disease-Free Survival

Disease-free survival was defined as the time from date of surgery to date of first evidence of cancer recurrence in the breast (ie, local or distant recurrence or contra lateral disease) or death from any cause, whichever came first. Patients who were alive or withdrawn from the study and had no evidence of disease recurrence and for whom there was CRF evidence that evaluations had been made were censored at the date of the last clinical follow-up assessment when the patient was known to be disease free.

Time frame:
30 - 1102 days
Reported as:
Number · participants
Participants With Disease-Free Survival
participantsHER2-Neu NegativeHER2-Neu Positive
Participants With Disease-Free Survival9225
SecondaryParticipants With Overall Survival

Overall survival was defined as the time from date of start of study treatment to the date of death, regardless of the cause of death. Patients who were alive at the time of the analysis were censored at the date of the last follow-up assessment. Patients without follow-up assessment were censored at the day of the last dose. Patients with no post-baseline information were censored at the start of study treatment.

Time frame:
22 - 1191 days
Reported as:
Number · participants
Participants With Overall Survival
participantsHER2-Neu NegativeHER2-Neu Positive
Participants With Overall Survival11832

Adverse events

Collected over Cycle 1, Cycle 2, Cycle 3, Cycle 4, at Surgery, and the month 1 visit during the postoperative follow-up period. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
HER2-Neu Negative—15/122 (12.3%)121/122 (99.2%)
HER2-Neu Positive—7/34 (20.6%)33/34 (97.1%)
Most frequent serious events
Showing 10 of 23
Most frequent serious events
EventHER2-Neu NegativeHER2-Neu Positive
febrile neutropeniaBlood and lymphatic system disorders4/1221/34
PneumoniaInfections and infestations1/1221/34
InfectionInfections and infestations0/1221/34
Perirectal abscessInfections and infestations0/1221/34
NeutropeniaBlood and lymphatic system disorders0/1221/34
International normalised ratio increasedInvestigations0/1221/34
Prothrombin time prolongedInvestigations0/1221/34
PresyncopeNervous system disorders0/1221/34
NephrolithiasisRenal and urinary disorders0/1221/34
HypotensionVascular disorders0/1221/34
Most frequent other events
Showing 10 of 58
Most frequent other events
EventHER2-Neu NegativeHER2-Neu Positive
Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders57/12221/34
FatigueGeneral disorders62/12220/34
NauseaGastrointestinal disorders57/12219/34
DiarrhoeaGastrointestinal disorders51/12219/34
AlopeciaSkin and subcutaneous tissue disorders59/12212/34
StomatitisGastrointestinal disorders18/12214/34
InsomniaPsychiatric disorders27/12212/34
AnaemiaBlood and lymphatic system disorders7/12210/34
NeutropeniaBlood and lymphatic system disorders31/1229/34
ConstipationGastrointestinal disorders30/1226/34

Baseline characteristics

Age Continuous
Age Continuous(years)HER2-Neu NegativeHER2-Neu PositiveTotal
Mean51.0 ± 11.2052.2 ± 9.3651.3 ± 10.79
Sex: Female, Male
Sex: Female, Male(Participants)HER2-Neu NegativeHER2-Neu PositiveTotal
Female12234156
Male000
08

Study locations

38 sites
  • Los Angeles, California 90057, United States
  • Montebello, California 90640, United States
  • Palm Springs, California 92262, United States
  • San Diego, California 92123, United States
  • Farmington, Connecticut 06030, United States
  • Melbourne, Florida 32910, United States
  • Miami, Florida 33136, United States
  • Tamarac, Florida 33321, United States
  • Savannah, Georgia 31405, United States
  • Indianapolis, Indiana 46227, United States
  • Indianapolis, Indiana 46260, United States
  • Iowa City, Iowa 52242, United States
  • Alexandria, Louisiana 71301, United States
  • Scarborough, Maine 04074, United States
  • Baltimore, Maryland 21201, United States
  • Edina, Minnesota 55435, United States
  • Jefferson City, Missouri 65109, United States
  • Rolla, Missouri 65401, United States
  • St Louis, Missouri 63141, United States
  • Neptune City, New Jersey 07754, United States
  • Albuquerque, New Mexico 87102, United States
  • Albuquerque, New Mexico 87108, United States
  • Albuquerque, New Mexico 87131-5636, United States
  • Santa Fe, New Mexico 87505, United States
  • New York, New York 10003, United States
  • Charlotte, North Carolina 28233-3549, United States
  • Canton, Ohio 44718, United States
  • Pittsburgh, Pennsylvania 15213, United States
  • Pottsville, Pennsylvania 17901, United States
  • Charleston, South Carolina 29425, United States
  • Georgetown, South Carolina 29442, United States
  • Sumter, South Carolina 29150, United States
  • Memphis, Tennessee 38104, United States
  • Memphis, Tennessee 38120, United States
  • Dallas, Texas 75231, United States
  • Dallas, Texas 75390-9034, United States
  • Burlington, Vermont 05401, United States
  • Abingdon, Virginia 24211, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2005, a primary completion of Apr 2009 and a completion of Jul 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2011, 2 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 5, 2005
First posted
Aug 9, 2005
Start
Aug 2005
Primary completionActual
Apr 2009
CompletionActual
Jul 2009
Results first posted
Aug 10, 2011
Last update
Aug 10, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 10, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00127933
Lead sponsor
Hoffmann-La Roche
First posted
Aug 9, 2005
Start date
Aug 2005
Primary completion
Apr 2009
Completion
Jul 2009
Results posted
Aug 10, 2011
Last update
Aug 10, 2011

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Docetaxel

Start the discussion